Sino Biopharmaceutical Brand Guidelines: CP Group’s Drug Maker and Chia Tai Tianqing

A Thai group’s drug business in China.

Sino Biopharmaceutical, which now calls itself SBP Group, describes itself as the pharmaceutical business in China of Thailand’s Charoen Pokphand Group, the Thai conglomerate. Chinese Wikipedia says the company was spun off from the Thai group in 2000. It first listed on Hong Kong’s Growth Enterprise Market on 29 September 2000 and moved to the exchange’s Main Board on 8 December 2003, Chinese Wikipedia says; its stock code is 1177.

English Wikipedia and the company’s own profile trace its rise through Hong Kong’s indices: the MSCI China Index in 2013, the Hang Seng Index in 2018, the Hang Seng China Enterprises Index in 2019, and two further Hang Seng indices in 2020.

Its largest operating company is older than the listed group. Chia Tai Tianqing, based in Lianyungang in Jiangsu province, sets out its history on its own website. It says it began in 1969 as the pharmaceutical factory of the first division of the Jiangsu Production and Construction Corps, was renamed the Lianyungang Dongfeng Pharmaceutical Factory in 1975, and became the Jiangsu Tianqing Pharmaceutical Factory in 1994. In 1997, it says, a joint venture with the CP pharmaceutical group created Lianyungang Chia Tai Tianqing Pharmaceutical; the business took the name Jiangsu Chia Tai Tianqing in 2001 and Chia Tai Tianqing Pharmaceutical Group in 2013, and marked fifty years of production in 2019.

Chinese Wikipedia names Tse Ping, a former executive vice-president of the Charoen Pokphand Group, as chairman of the CP pharmaceutical group and of Sino Biopharmaceutical, and says he stepped down as the listed company’s chief executive in August 2020. The company’s own record of events for 2025 names Theresa Tse as chairwoman of the board and Eric Tse as chief executive.

Liver medicines first, then cancer.

Chia Tai Tianqing built its name on liver medicines. Its history page says that in 1988 it launched its first liver drug, developed with partners, and made liver medicine the main direction of the business; later products in its own account include glycyrrhizin-based liver treatments in the 1990s and 2000s, its first cancer drug in 2004, and the hepatitis B antiviral entecavir in 2010. It now groups its products into six clusters: liver disease, oncology, respiratory, infection, endocrinology, and heart and brain medicines. Chinese Wikipedia describes the listed group’s output in terms of dosage forms: large- and small-volume injections, tablets, capsules, granules and powders.

Its most widely reported own drug is anlotinib, an oral cancer treatment the company launched in 2018 under the Chinese name Fukewei. Chinese Wikipedia, citing a company announcement, says China’s National Medical Products Administration approved a third use for it in September 2019. The group’s 2025 events list records a combination of anlotinib with penpulimab, a PD-1 antibody developed with Akeso and first approved in China in 2021, approved in December 2025 for first-line treatment of advanced liver cancer; the company calls that the tenth approved use of anlotinib.

The group says its subsidiaries also include Beijing Tide Pharmaceutical, invoX Pharma, and the wholly owned research companies LaNova Medicines and Hygieia. It says it has drug research and manufacturing bases in Beijing, Shanghai, Guangzhou, Nanjing and Lianyungang, a research team of more than 2,900, and four main therapeutic areas: oncology, liver and cardiometabolic disease, respiratory and autoimmune disease, and surgery and analgesia.

Chia Tai Tianqing says it moved its global research headquarters to Shanghai in 2023 and that more than ten of its products are approved in over sixty countries and regions.

How the category presents itself.

Korean and Chinese drug makers tend to introduce themselves through places as much as products. Their annual reports and websites lead with research campuses: new buildings in Shanghai and Suzhou, and the technology district of Pangyo, south of Seoul. Chia Tai Tianqing, for example, says it moved its global research headquarters to Shanghai in 2023, and Hengrui says it opened research offices in Princeton and Basel in 2020.

The pictures inside those reports follow a familiar pattern. White-coated scientists work at screens and fume hoods; long packaging lines carry tablets and vials; and the older companies keep a place for their beginnings, with founders and first factories shown in archive photographs. Several of the businesses in this group began as municipal or state factories decades before they became listed research companies.

Trade fairs are the other stage. The companies take booths at the BIO International Convention in the United States and at the large pharmaceutical fairs in China, where licensing talks with international partners are now a regular part of the business. Hengrui’s July 2025 licensing agreement with GSK is one recent example. In this guide, such deals are named without sums, and any deal not confirmed as completed is described as pending.

The visual identities themselves are mostly corporate and restrained: usually a wordmark in red, blue or green, with photography doing most of the work. Few of these companies publish brand guidelines or official colour values, so the palettes in this guide are our own unofficial interpretations, chosen to sit alongside the companies’ public materials without copying them.

From domestic generics to licensing abroad.

The group has also begun licensing its own candidates to international companies. On 8 July 2026, Yicai Global reported that Chia Tai Tianqing would grant AstraZeneca rights to develop, make and sell TQC3721, an inhaled dual PDE3/4 inhibitor, with a global licence including China for certain development programmes. A nebulised form was in Phase III trials for chronic obstructive pulmonary disease in China and a dry-powder form in Phase II, Yicai said, and the deal, announced in July 2026, remained subject to regulatory approval at the time of that report.

Yicai described Sino Biopharmaceutical as a Beijing-based company, and the group’s website gives both a Beijing and a Hong Kong headquarters. The older web address, sinobiopharm.com, now forwards to sbpgroup.com, and the group uses the short name SBP Group in its own communications.

The company’s stated philosophy is “Science for a Healthier World,” and its stated vision is “to be a leading global pharmaceutical company through delivering innovative therapies for patients.” It says it has appeared on a leading American list of the top 50 global pharmaceutical companies for seven years in a row, and on Forbes’ list of Asia’s best public companies for three.

For a design guide, Sino Biopharmaceutical shows a conglomerate’s name, a provincial factory’s history and a Hong Kong listing held together under one group identity. Compare Hengrui, another drug maker that grew from a Lianyungang factory, and CSPC. For this guide we use a deep pine, a mid green and an amber with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Sino Biopharmaceutical’s identity on hand — save it to a board in the Made Good inspiration library.